Bristol-Myers Squibb was granted a patent for anti-CCR8 cancer antibodies.

{
  "signal_id": "e5236222-ed5a-51fb-a064-f357ec4b6ec9",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-09-30T16:59:17+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07K 16/2866"
      },
      {
        "code": "A61P 35/00"
      },
      {
        "code": "C07K 16/2818"
      },
      {
        "code": "A61K 2039/505"
      },
      {
        "code": "A61K 2039/507"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Medical Research"
    ],
    "detail": "In September 2026 Bristol-Myers Squibb patented antibody treatments for targeting CCR8-bearing cells in cancer therapy, either alone or alongside other treatments.",
    "summary": "Bristol-Myers Squibb was granted a patent for anti-CCR8 cancer antibodies.",
    "event_at": "2026-09-29",
    "inventors": [
      {
        "name": "Ruth Yin-Zong Lan",
        "status": "resolved",
        "is_primary": true,
        "linkedin_url": "https://www.linkedin.com/in/ruth-lan-23171a20"
      },
      {
        "name": "Olufemi A. Adelakun",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Ishita Barman",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/ishitabarman"
      },
      {
        "name": "Joseph Richard Campbell",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "SJ Jian Zhe Diong",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Felix Findeisen",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Danielle M. Greenawalt",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/daniellegreenawalt"
      },
      {
        "name": "Renu Jain",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/renu-jain-67195b1b"
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-09-29",
    "source_url": "https://patents.google.com/patent/US12747296",
    "cpc_primary": {
      "code": "C07K 16/2866"
    },
    "patent_title": "Anti-CCR8 antibodies for treating cancer",
    "patent_number": "US12747296",
    "uspto_assignee": "BRISTOL-MYERS SQUIBB COMPANY",
    "patent_abstract": "This disclosure provides isolated antibodies, for example, monoclonal antibodies, that specifically bind to the C-C Motif Chemokine Receptor 8 (CCR8) expressed on the surface of a cell and mediate depletion of the CCR8-expressing cell by anti-body-dependent cellular cytotoxicity (ADCC). The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CCR8 antibody as monotherapy or in combination with an anti-cancer agent such as an immune checkpoint inhibitor, for example, an anti-PD-1 or anti-PD-L1 antibody.",
    "precision_class": "structural",
    "invention_explanation": "An antibody that attaches to CCR8 on cancer-associated cells and helps the immune system destroy those cells through antibody-dependent cellular cytotoxicity.",
    "technologies_mentioned": [
      "monoclonal antibodies",
      "immuno-oncology",
      "antibody-dependent cellular cytotoxicity",
      "CCR8 targeting"
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/e5236222-ed5a-51fb-a064-f357ec4b6ec9 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bms.com","limit":20}'